Compounding Chemotherapy Market: By Dose Type, By Compounding Type, Currently Unavailable Pharmaceutical Manufacturing, Pharmaceutical Dosage Alteration, By Delivery Method, Volumetric Automated Compounding Device ), By Sterility, By Technology, and Geography
| 1. Executive Summary |
| 2. Global Compounding Chemotherapy Market Introduction |
| 2.1. Global Compounding Chemotherapy Market – Taxonomy |
| 2.2. Global Compounding Chemotherapy Market –Definitions |
| 2.2.1. By Dose Type |
| 2.2.2. By Compounding Type |
| 2.2.3. By Delivery Method |
| 2.2.4. By Sterility |
| 2.2.5. By Technology |
| 2.2.6. By Region |
| 3. Global Compounding Chemotherapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Compounding Chemotherapy Market Dynamic Factors - Impact Analysis |
| 3.6. Global Compounding Chemotherapy Market – Competition Landscape |
| 4. Global Compounding Chemotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 |
| 4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Compounding Chemotherapy Market, By Dose Type, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 5.1. Chemotherapeutic |
| 5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Non-Chemotherapeutics |
| 5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Global Compounding Chemotherapy Market, By Compounding Type, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 6.1. Pharmaceutical Ingredient Alteration (PIA) |
| 6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM) |
| 6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Pharmaceutical Dosage Alteration (PDA) |
| 6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Compounding Chemotherapy Market, By Delivery Method, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 7.1. Gravimetric Automated Compounding Device (weight-based) |
| 7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Volumetric Automated Compounding Device (volume-based) |
| 7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8. Global Compounding Chemotherapy Market Forecast, By Sterility, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 8.1. Sterile |
| 8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Non-sterile |
| 8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9. Global Compounding Chemotherapy Market Forecast, By End User, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 9.1. With Robotic Arms |
| 9.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Without Robotic Arms |
| 9.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 10. Global Compounding Chemotherapy Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 10.1. North America |
| 10.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.1.3. Market Opportunity Analysis |
| 10.2. Europe |
| 10.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.2.3. Market Opportunity Analysis |
| 10.3. Asia-Pacific |
| 10.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.3.3. Market Opportunity Analysis |
| 10.4. Latin America |
| 10.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.4.3. Market Opportunity Analysis |
| 10.5. Middle East and Africa |
| 10.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.5.3. Market Opportunity Analysis |
| 10.6. Global Compounding Chemotherapy Market - Opportunity Analysis Index, By Dose Type, By Compounding Type, By Delivery Method, By Sterility, By Technology, and Region, 2022-2028 |
| 11. North America Compounding Chemotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 11.1. Dose Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Chemotherapeutic |
| 11.1.2. Non-Chemotherapeutics |
| 11.1.3. Others |
| 11.2. Compounding Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Pharmaceutical Ingredient Alteration (PIA) |
| 11.2.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM) |
| 11.2.3. Pharmaceutical Dosage Alteration (PDA) |
| 11.3. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Gravimetric Automated Compounding Device (weight-based) |
| 11.3.2. Volumetric Automated Compounding Device (volume-based) |
| 11.4. Sterility Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Sterile |
| 11.4.2. Non-sterile |
| 11.5. Technology Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. With Robotic Arms |
| 11.5.2. Without Robotic Arms |
| 11.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.6.1. USA |
| 11.6.2. Canada |
| 11.7. North America Compounding Chemotherapy Market - Opportunity Analysis Index, By Dose Type, By Compounding Type, By Delivery Method, By Sterility, By Technology, and Country, 2022-2028 |
| 11.8. North America Compounding Chemotherapy Market Dynamics – Trends |
| 12. Europe Compounding Chemotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 12.1. Dose Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Chemotherapeutic |
| 12.1.2. Non-Chemotherapeutics |
| 12.1.3. Others |
| 12.2. Compounding Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Pharmaceutical Ingredient Alteration (PIA) |
| 12.2.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM) |
| 12.2.3. Pharmaceutical Dosage Alteration (PDA) |
| 12.3. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gravimetric Automated Compounding Device (weight-based) |
| 12.3.2. Volumetric Automated Compounding Device (volume-based) |
| 12.4. Sterility Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Sterile |
| 12.4.2. Non-sterile |
| 12.5. Technology Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. With Robotic Arms |
| 12.5.2. Without Robotic Arms |
| 12.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.6.1. Germany |
| 12.6.2. UK |
| 12.6.3. France |
| 12.6.4. Spain |
| 12.6.5. Italy |
| 12.6.6. Russia |
| 12.6.7. Rest of Europe |
| 12.7. Europe Compounding Chemotherapy Market - Opportunity Analysis Index, By Dose Type, By Compounding Type, By Delivery Method, By Sterility, By Technology, and Country, 2022-2028 |
| 12.8. Europe Compounding Chemotherapy Market Dynamics – Trends |
| 13. Asia-Pacific Compounding Chemotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 13.1. Dose Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Chemotherapeutic |
| 13.1.2. Non-Chemotherapeutics |
| 13.1.3. Others |
| 13.2. Compounding Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Pharmaceutical Ingredient Alteration (PIA) |
| 13.2.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM) |
| 13.2.3. Pharmaceutical Dosage Alteration (PDA) |
| 13.3. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Gravimetric Automated Compounding Device (weight-based) |
| 13.3.2. Volumetric Automated Compounding Device (volume-based) |
| 13.4. Sterility Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Sterile |
| 13.4.2. Non-sterile |
| 13.5. Technology Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. With Robotic Arms |
| 13.5.2. Without Robotic Arms |
| 13.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.6.1. China |
| 13.6.2. India |
| 13.6.3. Japan |
| 13.6.4. ASEAN |
| 13.6.5. Australia & New Zealand |
| 13.6.6. Rest of Asia-Pacific |
| 13.7. Asia-Pacific Compounding Chemotherapy Market - Opportunity Analysis Index, By Dose Type, By Compounding Type, By Delivery Method, By Sterility, By Technology, and Country, 2022-2028 |
| 13.8. Asia-Pacific Compounding Chemotherapy Market Dynamics – Trends |
| 14. Latin America Compounding Chemotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 14.1. Dose Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. Chemotherapeutic |
| 14.1.2. Non-Chemotherapeutics |
| 14.1.3. Others |
| 14.2. Compounding Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1. Pharmaceutical Ingredient Alteration (PIA) |
| 14.2.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM) |
| 14.2.3. Pharmaceutical Dosage Alteration (PDA) |
| 14.3. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Gravimetric Automated Compounding Device (weight-based) |
| 14.3.2. Volumetric Automated Compounding Device (volume-based) |
| 14.4. Sterility Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Sterile |
| 14.4.2. Non-sterile |
| 14.5. Technology Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. With Robotic Arms |
| 14.5.2. Without Robotic Arms |
| 14.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 14.6.1. Brazil |
| 14.6.2. Mexico |
| 14.6.3. Rest of Latin America |
| 14.7. Latin America Compounding Chemotherapy Market - Opportunity Analysis Index, By Dose Type, By Compounding Type, By Delivery Method, By Sterility, By Technology, and Country, 2022-2028 |
| 14.8. Latin America Compounding Chemotherapy Market Dynamics – Trends |
| 15. Middle East and Africa Compounding Chemotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
| 15.1. Dose Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 15.1.1. Chemotherapeutic |
| 15.1.2. Non-Chemotherapeutics |
| 15.1.3. Others |
| 15.2. Compounding Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
| 15.2.1. Pharmaceutical Ingredient Alteration (PIA) |
| 15.2.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM) |
| 15.2.3. Pharmaceutical Dosage Alteration (PDA) |
| 15.3. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.3.1. Gravimetric Automated Compounding Device (weight-based) |
| 15.3.2. Volumetric Automated Compounding Device (volume-based) |
| 15.4. Sterility Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.4.1. Sterile |
| 15.4.2. Non-sterile |
| 15.5. Technology Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.5.1. With Robotic Arms |
| 15.5.2. Without Robotic Arms |
| 15.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 15.6.1. Gulf Cooperation Council (GCC) Countries |
| 15.6.2. South Africa |
| 15.6.3. Rest of MEA |
| 15.7. MEA Compounding Chemotherapy Market - Opportunity Analysis Index By Dose Type, By Compounding Type, By Delivery Method, By Sterility, By Technology, and Country, 2022-2028 |
| 15.8. MEA Compounding Chemotherapy Market Dynamics – Trends |
| 16. Competition Landscape |
| 16.1. Strategic Dashboard of Top Market Players |
| 16.2. Company Profiles (Introduction, Financial Analysis, Key Dose Types, Key Developments, Strategies, and SWOT Analysis) |
| 16.2.1. Pharma B.V. |
| 16.2.2. Arxium, Inc. |
| 16.2.3. Baxter International Inc. |
| 16.2.4. B. Braun Melsungen AG |
| 16.2.5. Comecer S.P.A. |
| 16.2.6. Dedalus S.P.A. |
| 16.2.7. Equashield, LLC. |
| 16.2.8. Grifols |
| 16.2.9. Icon Group |
| 16.2.10. Loccioni Group. |
| 16.2.11. Miller Pharmacy Inc. |
| 16.2.12. Omnicell, Inc. |
| 16.2.13. Pfizer, Inc. |
| 17. Research Methodology |
| 18. Key Assumptions and Acronyms |
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
